The AAA-ATPase VCP (also known as p97) cooperates with distinct cofactors to process ubiquitylated proteins in different cellular pathways [1] [2] [3] . VCP missense mutations cause a systemic degenerative disease in humans, but the molecular pathogenesis is unclear 4,5 . We used an unbiased mass spectrometry approach and identified a VCP complex with the UBXD1 cofactor, which binds to the plasma membrane protein caveolin-1 (CAV1) and whose formation is specifically disrupted by disease-associated mutations. We show that VCP-UBXD1 targets mono-ubiquitylated CAV1 in SDS-resistant high-molecular-weight complexes on endosomes, which are en route to degradation in endolysosomes 6 . Expression of VCP mutant proteins, chemical inhibition of VCP, or siRNA-mediated depletion of UBXD1 leads to a block of CAV1 transport at the limiting membrane of enlarged endosomes in cultured cells. In patient muscle, muscle-specific caveolin-3 accumulates in sarcoplasmic pools and specifically delocalizes from the sarcolemma. These results extend the cellular functions of VCP to mediating sorting of ubiquitylated cargo in the endocytic pathway and indicate that impaired trafficking of caveolin may contribute to pathogenesis in individuals with VCP mutations.
are many uncharacterized cofactors, VCP is thought to have many yet unidentified cellular functions 9, 10 . VCP missense mutations in humans cause a dominant late-onset systemic degenerative disorder, IBMPFD (inclusion body myopathy associated with Paget's disease of bone and fronto-temporal dementia), also called VCP disease 4, 5 . Although cellular defects associated with IBMPFD mutations have been proposed [11] [12] [13] [14] [15] , the molecular pathogenesis has remained unclear because VCP is essential and patients develop normally until their fourth or fifth decade. As mutant VCP still binds to the main cofactors p47 (also known as NSFL1C) or UFD1-NPL4 (also known as UFD1L-NPLOC4, ubiquitin fusion degradation 1 like-nuclear protein localization 4 homologue) and its ATP hydrolysis activity is only mildly affected at most 15, 16 , we reasoned that an as yet unidentified function may be specifically affected by the mutations in VCP.
To identify such a function, we used an unbiased mass spectrometry approach (Fig. 1a) to search for a distinct VCP cofactor or substrate, whose interaction may specifically be compromised by the most common disease-associated mutation, R155H (RH; ref. 4) . We induced mild overexpression of Myc/Strep-tagged VCP RH in stable HEK293 cells. For comparison, we expressed wild-type VCP or the ATPase-deficient substrate-trapping mutant E578Q (EQ; refs 17, 18) . Tandem isolation revealed that tagged VCP integrated with endogenous VCP hexamers in a roughly 1:1 ratio (Fig. 1b) . We analysed associated proteins using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and compared interaction partners identified with a high probability of ≥99% (ref. 19 ; Fig. 1a and Supplementary Table S1 ). Eight common cofactors including components of the endoplasmic reticulum-associated degradation system were consistently identified in all samples independent of the VCP variant, implying that the main processes are not affected by the disease-associated VCP Figure 1 The VCP-UBXD1 chaperone complex binds to caveolin, and this interaction is specifically disrupted by IBMPFD-associated mutations in VCP. (a) Mass spectrometry-based strategy to identify differences in the interaction pattern of wild-type VCP, the disease-associated mutant RH or the ATPase-deficient mutant EQ. Left, Myc/Strep-tagged VCP variants were doxycycline (DOX)-induced and tandem isolated from stable HEK293 cell lines. Right, associated proteins were detected in a shotgun approach and high-probability (≥99%) candidates are represented in a Venn diagram. For full details, see Supplementary Table S1 mutation in the HEK293 cells, and consistent with a previous report 11 . This was supported by analysis with the X-box binding protein 1 (XBP1) DBD -Venus reporter assay 20 showing that the endoplasmic reticulum unfolded protein response was not induced by VCP RH overexpression, in contrast to VCP EQ ( Supplementary Fig. S1a ). Importantly however, we identified a new VCP binding factor CAV1 as a high-probability hit both in wild-type and EQ, but not in RH isolates (Fig. 1a) . Western blot analysis confirmed that CAV1 bound to VCP and that this interaction was specifically compromised by the RH mutation (Fig. 1b) . In addition, we detected the UBX domain protein 1 (UBXD1; also known as UBXN6) cofactor 9, 21 in EQ isolates (Fig. 1a,b) , and found that it also co-isolated with wild-type VCP at lower levels, but not with the RH mutant (Fig. 1b) . Binding of UBXD1 and CAV1 to two other IBMPFD-associated VCP mutants, R95G and A232E (AE), was also affected ( Supplementary Fig. S1c ), implying that compromised binding of VCP to UBXD1 and CAV1 is a general defect underlying the disease. In all cases, the interaction of the VCP mutant proteins with the main cofactors p47 and UFD1-NPL4 was slightly increased (Fig. 1b and Supplementary Fig. S1c ), as recently reported 15 . Next, we investigated whether VCP, UBXD1 and CAV1 form a single complex. Sequential isolation of VCP by virtue of its Strep-tag from cells overexpressing all three factors, followed by native elution and immunoprecipitation of UBXD1 co-isolated CAV1, indicating that they form a ternary complex ( Supplementary Fig. S1d ). Direct isolation of overexpressed UBXD1 from cells expressing wild-type VCP and VCP RH further supported this notion and confirmed that the level of CAV1 binding to UBXD1 was decreased in the RH background (Fig. 1c) . Immunoprecipitation of endogenous UBXD1 or p47 with specific antibodies showed that the interaction with CAV1 was specific for the VCP-UBXD1 complex, which did not contain any of the other main cofactors, p47 or UFD1-NPL4 (Fig. 1d ). These results demonstrate that UBXD1 defines an alternative VCP complex, which binds to CAV1 and whose formation is specifically compromised by disease-associated mutation of VCP.
CAV1, and its isoforms caveolin-2 and the muscle-specific caveolin-3 (CAV3), are membrane proteins that form the main constituent of caveolae 22 . Caveolae are invaginations of the plasma membrane that define cholesterol-rich microdomains, which are important for signalling, endocytosis and maintenance of the plasma membrane 22 . CAV1 is synthesized in the endoplasmic reticulum and assembles along the membranes of the secretory pathway into large caveolar domains [23] [24] [25] plasma membrane and endosomes 26, 27 . For degradation, CAV1 is modified with mono-ubiquitin, a signal important for endosomal sorting 28 , and transported to intraluminal vesicles in endolysosomes 6 . In other cellular processes, VCP targets ubiquitin-modified substrate proteins [1] [2] [3] . We therefore initially confirmed that CAV1 is conjugated predominantly with mono-ubiquitin in HEK293 cells (Fig. 2a) . We then showed in sequential immunoprecipitations that CAV1 associated with VCP in the ubiquitylated form in addition to the unmodified form (Fig. 2b) . To determine whether ubiquitylation is essential for the interaction with VCP, we analysed a CAV1 K * R variant, in which all 12 lysines were mutated to arginine. CAV1 K * R still travels to early endosomes, but cannot be ubiquitylated and transported to endolysosomes 6 ( Supplementary Fig. S2 ). Indeed, co-immunoprecipitations revealed that binding to VCP was abolished ( Fig. 2c) , implying that CAV1 ubiquitylation is important for targeting by VCP.
During maturation, CAV1 first forms SDS-resistant oligomers that associate to form larger assemblies in a cholesterol-dependent manner during exit from the Golgi apparatus 23, 24, 29, 30 . Similarly to other AAA-type ATPases, VCP uses the energy of ATP hydrolysis to segregate proteins from stable complexes for further processing 17, 18, 31 . We therefore investigated whether VCP targets SDS-resistant CAV1 oligomers. Lysates of CV-1 control cells, and of CV-1 cells expressing wild-type VCP or VCP RH , were separated on SDS gels without prior boiling and exhibited a typical pattern of SDS-resistant CAV1 complexes above the apparent relative molecular mass of 200,000 (M r 200K) in western blots 29 ( Fig. 2d) . Isolation of VCP revealed that the associated CAV1 was enriched in such complexes when compared with the monomeric form in the case of wild-type cells, showing that indeed VCP targets CAV1 oligomers. As expected, VCP RH did not bind to either of the two forms.
To confirm the observed selectivity of VCP for these oligomers, we used two methods to disrupt oligomerization. First, we expressed a CAV1 variant with the P132L mutation that is defective in oligomerization 32 . Second, we depleted plasma membrane pools of cholesterol with the inhibitor U18666A (ref. 23 ). In both cases, the level of VCP binding in pulldown experiments was decreased or abolished ( Fig. 2e and Supplementary Fig. S1e ). The large assemblies separate from the individual SDS-resistant complexes in velocity centrifugation gradients with sedimentation coefficients of 70S and 8S, respectively 23 . Both peaks sedimented normally in lysates from cells expressing wild-type VCP or VCP RH , whereas the 70S selectively shifted to the bottom of the gradient in VCP EQ lysates ( Supplementary Fig. S1f ). Together, these data provide biochemical evidence implying that the VCP-UBXD1 complex binds to the caveolin oligomers that occur post-Golgi at or near the plasma membrane.
To confirm this notion morphologically, we assessed co-localization of CAV1-GFP (green fluorescent protein) with UBXD1-mCherry overexpressed in live U2OS cells. CAV1 localized to caveolae at the plasma membrane in addition to larger intracellular structures (Fig. 3a) . UBXD1 specifically co-localized with CAV1 to these structures, in addition to its diffuse cytosolic distribution (Fig. 3a) . The intracellular structures were the previously described endocytic compartments 6 , because they co-localized with GFP fusions of markers for early and late endosomes, RAB5 (also known as RAB5A, member RAS oncogene family), RAB7 (also known as RAB7A) and LAMP1 (lysosomalassociated membrane protein 1; Supplementary Fig. S2a,b) . Consistent with the biochemical analysis, recruitment of UBXD1 to endosomes required ubiquitylation of CAV1, because UBXD1 did not associate with endosomes in cells transfected with the CAV1 K * R variant that failed to be ubiquitylated ( Supplementary Fig. S2c-f) .
Next, we investigated whether VCP and UBXD1 were essential for trafficking of CAV1 to endolysosomes and whether diseaseassociated mutants were defective in the process. In the first approach, we induced expression of VCP mutants in stable U2OS cells transiently expressing CAV1-RFP (red fluorescent protein) along with LAMP1-GFP as a marker for late endosomes and lysosomes. CAV1 co-localized with LAMP1 in control cells (Fig. 3b) , confirming that part of it was transported to endolysosomes 6 . Strikingly however, CAV1 in VCP RH -and more so in VCP EQ -expressing cells localized to enlarged LAMP1-positive vesicles that appeared as early as 24 h after induction of mutant VCP (Fig. 3b,c) . Importantly, CAV1 was restricted to the limiting membrane of these vesicles, which points to a defect in processing and transport of CAV1 to intraluminal vesicles. Ultrastructural analysis revealed that the number of multivesicular bodies (MVBs) was indeed decreased in cells expressing VCP EQ , VCP RH or another disease-associated mutant, VCP AE (Fig. 3d,e and Supplementary Fig. S3a ). Instead, we observed an increased number of vacuoles that were empty or contained only few intraluminal vesicles. Further fluorescence microscopy analysis using the pH-sensitive lysotracker probe revealed that the aberrant CAV1/LAMP1-rimmed vesicles failed to acidify ( Supplementary  Fig. S3b ). They were not autophagosomes, because they did not contain the autophagy marker LC3 (also known as MAP1LC3A, microtubule-associated protein 1 light chain 3α; Supplementary  Fig. S3c ). Cellular depletion of UBXD1 by short interfering RNA (siRNA) also specifically affected transport of CAV1, as shown by an increase in the number of enlarged CAV1/RAB5-positive endosomes (Fig. 3f-h ). These data show that binding and activity of VCP and its cofactor UBXD1 are required for proper sorting of CAV1 to endolysosomes.
In an additional approach, we applied the VCP small-molecule inhibitor DBeQ (ref. 33 ). Treatment for 6 h induced accumulation of overexpressed CAV1-GFP at enlarged LAMP1-rimmed vesicles, exceeding the effect of VCP EQ expression markedly (Fig. 4a) . Even without overexpression of CAV1, DBeQ caused an enlargement of LAMP1-positive late endosomes/lysosomes and an accumulation of CAV1 in more than 80% of these structures (Fig. 4b) , implying that acute and penetrant inhibition of VCP affects trafficking also of endogenous CAV1. Next, we investigated whether inhibition of VCP had a more general impact on the cargo of the endocytic pathway and assessed degradation of the epidermal growth factor receptor (EGFR). After epidermal growth factor (EGF) stimulation, the EGFR was endocytosed normally in control and DBeQ-treated cells, as visualized by immunohistochemistry, but then persisted longer in intracellular pools in DBeQ-treated cells when compared with control-treated cells (Fig. 4c) . The delayed degradation of the EGFR was also confirmed by western blot analysis (Fig. 4d) . Chemical inhibition thus confirmed the role of VCP in CAV1 trafficking and revealed a more general involvement in endosomal sorting.
To assess whether the role of VCP in caveolin trafficking is relevant to IBMPFD patients, we first analysed cultured fibroblasts from three different patients harbouring two different VCP mutations (see Supplementary Table S2 for patient demographics). We compared the distribution of endogenous CAV1 and LAMP2 by immunofluorescence microscopy with cells from healthy individuals or patients with another degenerative disorder, sporadic amyotrophic lateral sclerosis (sALS). Again, CAV1 accumulated on the limiting membrane of enlarged vesicles that were positive for LAMP2 in IBMPFD patient cells when compared with control cells (Fig. 5a,b) . Consistently, the vesicles were not acidified and did not contain LC3 (data not shown). Next, we analysed CAV3 localization in muscle tissue from six different IBMPFD patients. Whereas CAV3 in healthy individuals exhibited the typical sarcolemmal localization, it accumulated in sacroplasmic pools that associated and partially overlapped with late endosomes in patient tissue ( Fig. 5c and Supplementary Fig. S4a) . Strikingly, CAV3 also specifically delocalized from the sacrolemma. This entailed delocalization of its partner protein cavin-1 (also known as PTRF, polymerase I and transcript release factor), but not of other plasma membrane proteins dysferlin, dystrophin and dystrophin-associated glycoproteins ( Supplementary Fig. S4b,c) .
These data provide evidence that disease-associated mutations of VCP specifically interfere with caveolin trafficking in cultured cells and patient tissue. VCP has well-established roles in facilitating proteasome-dependent degradation of polyubiquitylated proteins. Our results now link VCP and UBXD1 to ubiquitin-dependent membrane sorting at endosomes and degradation in lysosomes, and imply that this pathway is impaired in IBMPFD. VCP binds to a mono-ubiquitylated cargo substrate, CAV1, on endosomes and is critical for its transport to endolysosomes. Blocking VCP binding of CAV1 (with IBMPFD-associated mutations) or its protein segregase activity (with the EQ mutation or the DBeQ inhibitor) leads to accumulation of CAV1 at the limiting membrane of late endosomes. Given that VCP targets SDS-resistant CAV1 oligomers (Fig. 2) , one possible scenario is that VCP helps to segregate stable, SDS-resistant CAV1 assemblies to facilitate their transport to the lumen of endolysosomes. Cellular depletion of the UBXD1 cofactor also affected CAV1 trafficking (Fig. 3f,g ), but not the VCP-CAV1 interaction (data not shown), indicating that UBXD1 may help VCP in substrate-processing rather than acting as a substrate adapter. Interestingly, another cofactor, phospholipase A2-activating protein (PLAA; also known as UFD3) that we identified in our screen (Fig. 1a) was shown to function in sorting to late endosomes in yeast 34 , implying a conserved role of VCP in this process. Chemical inhibition of VCP also affected EGFR sorting, indicating that VCP is more generally involved in trafficking of endocytic cargo. Our results do not exclude that compromised interaction with other cofactors reported during the course of this study may be relevant 15 . At least in the case of the E4B (also known as UFD2) cofactor however, the decrease in the level of binding seems minor when compared with CAV1 and UBXD1 in our laboratory ( Supplementary Fig. S5 ). Taken together, we propose that impaired endosomal trafficking constitutes an important aspect in the cytopathology caused by IBMPFD-associated mutations.
Consistently, we show that VCP mutations are associated with CAV3 mislocalization in IBMPFD patient muscle, identical to that observed in transgenic mice expressing VCP RH (ref. 35) . Importantly, myopathycausing mutations in CAV3 result in a similar mislocalization 36 . These include a P104L missense mutation in CAV3, whose equivalent P132L in CAV1 abolishes VCP binding (Fig. 2e) . This supports the notion that CAV3 mislocalization in IBMPFD patient tissue may contribute to inclusion body myopathy pathogenesis. Impaired CAV1 and receptor sorting may also be relevant to Paget's disease of bone, which is commonly caused by defective ubiquitin-dependent signal transduction from the plasma membrane in osteoclasts 37 . Moreover, the third phenotypic feature in IBMPFD is fronto-temporal dementia. Of note, one pathologically similar form of fronto-temporal dementia is associated with mutations in CHMP2B, another factor that is essential for endosomal sorting and MVB biogenesis 38 . In analogy, impaired VCP-mediated endosomal sorting may therefore even be relevant for the pathogenesis in neurons. Missense mutations were introduced according to the Quikchange protocol and the total sequence was confirmed. Human UBXD1 was cloned with a C-terminal 3×haemagglutinin (HA)-tag or mCherry into pIRESpuro2 (Invitrogen). Constructs for CAV1-HA, CAV1-Myc, CAV1 K * R -Myc, CAV1-monomeric enhanced GFP and CAV1-RFP were described previously 6, 23 . LAMP1-GFP/-RFP, LC3-GFP and HA-ubiquitin were gifts from J. Gruenberg (University of Geneva, Switzerland), T. Yoshimori (National Institute of Genetics, Osaka, Japan) and P. DeCamilli (Yale University, USA), respectively.
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Methods
Cell culture and transfections. Stable inducible HEK293 cells expressing
Myc/Strep-tagged VCP variants were generated with the Flp-In T-REx system (Invitrogen) according to the manufacturer's protocol and single clones were selected. Stable inducible U2OS cell lines expressing VCP variants were described previously 14 . Cells were maintained in DMEM supplemented with 10% FCS in the presence of penicillin/streptomycin, and stable cell lines were additionally supplemented with 50 µg ml −1 hygromycin and 100 µg ml −1 zeocin (for U2OS) or 100 µg ml −1 hygromycine and 15 µg ml −1 blasticidine (for HEK293). Expression was induced by 1 µg ml −1 doxycycline. HEK293 cells were transfected using calcium phosphate, CV-1 using electroporation (AMAXA) and U2OS using were obtained under an approved IRB protocol at Washington University School of Medicine. All experiments were carried out with fibroblasts at a matched passage number of less than 10. One fibroblast line (GM20926) was obtained from Coriell Cell repositories. Fibroblasts were grown for 1-2 days, methanol-fixed and processed for immunodetection. For cell counting, >100 fibroblasts were counted from >10 randomly identified fields with a ×40 objective using two sets of coverslips/fibroblast culture. CAV1 immunoreactive vacuoles were identified as a full circle with an empty lumen. For statistics, each control or IBMPFD fibroblast line was treated as an independent experiment (therefore an N = 4, and the average and s.e.m. from these four control cell lines was calculated). Frozen tissue was sectioned (10 µM), acetone-fixed and processed for immunodetection. For some antibodies, a biotinylated secondary antibody was used and then detected using a Vectastain ABC kit (Vector Labs). Specimens were examined using a fluorescence microscope (Nikon 80i upright) and a Roper Scientific EZ monochrome CCD (charge-coupled device) camera with deconvolution software analysis (NIS Elements, Nikon) at room temperature.
Electron microscopy. For thin-section electron microscopy, cells were grown to 70% confluence in a 100 mm dish and induced to express VCP variants for 16 h. For sample preparation, trypsinized cells were collected, washed in phosphatebuffered saline (PBS), fixed in 2.5% glutaraldehyde in sodium cacodylate, embedded, sectioned and stained with uranyl acetate according to standard procedures. For quantification, 10 randomly generated 300 × 300 µm images were taken for each condition. An MVB was identified as a vacuole with a diameter of >200 nm containing three or more internal vesicles.
Statistical analysis. Statistical analyses were carried out with the unpaired twosided t -test. P < 0.05 ( * * ) was considered statistically significant.
Fluorescence imaging and co-localization analysis. For live-cell imaging, U2OS cells were seeded into µ-Slide 8-well chambers (Ibidi) one day before transfection or induction. Live-cell imaging was carried out using a Zeiss Axiovert 200 M microscope equipped with a Yokogawa CSU10 spinning-disc confocal unit and a temperature/CO 2 -controlled incubator. Images were acquired using a Hamamatsu C9100-13 EMCCD camera, an argon-krypton laser (Spectra Physics) and a ×100/1.4 NA PlanApo oil-immersion objective. Acquisition was driven by Metamorph (Molecular Devices). Alternatively, a Leica TCS SP5 laser scanning microscope, with a ×100/1.49 NA oil-immersion objective was used. For quantification of UBXD1-mCherry co-localization with CAV1-GFP or CAV1-HA, the JACoP plugin in ImageJ software 39 was used and the Manders' coefficient was calculated for signal overlap: the fraction of the UBXD1-mCherry signal overlapping with CAV1-GFP (Fig. 3a) or the fraction of the CAV1-HA immuno-signal overlapping with UBXD1-mCherry ( Supplementary Fig. S2d ). For quantification with endosomal markers, live cells were imaged using a Zeiss epifluorescence microscope equipped with a Hamamatsu camera, a 100 W HBO lamp and Metamorph software. Automated co-localization analysis was carried out using a Matlab routine to detect endosomal structures on epifluorescence images of live cells acquired with an Olympus IX71 system and to determine the overlap between D1-mCherry and endosomal markers as described previously 6 . Detected UBXD1-mCherry structures overlapping at least 40% with endosomal markers were considered co-localizing. For indirect immunofluorescence microscopy, cells were seeded on coverslips and fixed in 4% formaldehyde. Epifluorescence images were taken on a Nikon Eclipse Ti microscope with an Andor DR-328G-C01-SIL camera. For confocal images, a Yokogawa CSU-X1 unit attached to the same microscope was used and images were acquired with an Andor iXon X3 EMCCD camera.
Flow cytometry. Stable HEK293 cells were transfected with the pCAX-F-XBP1 DBD -Venus construct 20 and VCP variants were induced by doxycycline treatment. After 24 h, cells were fixed and XBP1-Venus intensities were measured at 488 nm in a FACSCalibur (BD Biosciences) flow cytometer.
